IDSA Addresses Clinical Utility of COVID-19 Antibody Testing in Updated Guidelines
Updated guidance from the IDSA suggests that the clinical utility of COVID-19 antibody testing is limited by the high global seroprevalence of anti-SARS-CoV-2 antibodies.